Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top line but saw significant GAAP EPS underperformance due to non-cash valuation adjustments. Revenue of $1.44M fell -24.05% short of the $1.90M consensus, primarily due to Zola® inventory shortages and shipping delays. Despite a -41% YoY widening of net loss attributable to common stockholders to $6.27M, management highlighted a positive inflection point in July/August sales and a drastically improved cash burn rate ($319K used in ops).
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Arcadia Biosciences(RKDA) the Revenue is 1.443 M (-0.82%);the EBIT is -496 K (+66.96%);the EPS is -2.09 (+35.79%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B0.82%
----
----
EBIT
-0.00B66.96%
----
----
EPS
-2.093935.79%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf